Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)
Not Applicable
Recruiting
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003124
- Lead Sponsor
- The affiliated Hospital to Changchun University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Vulnerable and high risk groups such as health care workers and non health care workers in health care settings. 2019-ncov.
Exclusion Criteria
1. A pregnant or lactating woman;
2. With other major diseases, such as serious heart, lung, liver, kidney damage or psychiatric patients. Participants should not take part in the study under any of the above circumstances. The Research Hospital and the applicant unit will not bear the responsibility if they intentionally conceal the medical history and medication history.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Chushifangyi's antiviral activity against SARS-CoV-2 variants?
How does Chushifangyi compare to standard-of-care antiviral treatments in preventing viral replication and disease progression?
What biomarkers are associated with response to Chushifangyi in high-risk populations for severe COVID-19?
What are the potential adverse events and safety monitoring strategies for Chushifangyi in clinical use?
Are there combination therapies involving Chushifangyi and Western antiviral drugs that enhance prevention efficacy?